HER2-Targeted Antibody Treatment for Ovarian Cancer Future Opportunities
- *Corresponding Author:
- Langdon SP
Division of Pathology, Institute of Genetics and Molecular Medicine
University of Edinburgh, Crewe Road South, Edinburgh EH4 2XU, United Kingdom
Tel: 0131 537 1763
E-mail: [email protected]
Received date: June 21, 2016; Accepted date: June 23, 2016; Published date: June 27, 2016
Citation: Langdon SP, Andrew H Sims (2016) HER2-Targeted Antibody Treatment for Ovarian Cancer – Future Opportunities. J Mol Pharm Org Process Res 4:e125. doi:10.4172/2329-9053.1000e125
Copyright: © 2016 Langdon SP, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
There are an estimated 240,000 new cases of ovarian cancer diagnosed worldwide each year . Due to late presentation, in many parts of the world it remains the most lethal gynecological cancer . In 2004, a new model description of this disease was proposed that combined both histopathological and molecular features and which classified epithelial ovarian cancers into two broad categories designated Type I and Type II tumors .